☆ 4.1 Article

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey

ANNALS OF SAUDI MEDICINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents

Maria Lucia Gomes Ferraz et al.

Summary: This study investigates the retreatment of hepatitis C in previously non-responders to direct antiviral agents (DAAs) in Brazil. The results of the survey show that retreatment is associated with a high sustained virological response rate in this sample of Brazilian patients. This finding suggests that the retreatment options available in the public health system in Brazil are effective and safe, and are an important component of the strategy to eliminate hepatitis C.

BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users

Jui-Ting Hsu et al.

Summary: This study compared the efficacy of DAA therapy for HCV infection in PWIDs and non-drug users, finding that PWIDs had higher proportions of HCV genotypes 3 and 6 but lower SVR rates compared to non-drug users. Risk factors associated with treatment failure included HIV coinfection and history of PWID.

MEDICINA-LITHUANIA (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection

Akio Miyasaka et al.

Summary: In a real-world clinical setting, treatment with glecaprevir/pibrentasvir has shown good efficacy and safety in Japanese patients with genotype 1/2 hepatitis C virus infection.

HEALTH SCIENCE REPORTS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naive adults with chronic hepatitis C virus genotypes 1-6 in Brazil

Mario Peribanez-Gonzaleza et al.

Summary: The study showed that glecaprevir/pibrentasvir was effective and well tolerated in treatment-naive Brazilian patients with hepatitis C infection without cirrhosis and with compensated cirrhosis.

ANNALS OF HEPATOLOGY (2021)

添加到收藏夹

Article Substance Abuse

Therapy of chronic hepatitis C in people who inject drugs: focus on adherence

Sona Frankova et al.

Summary: The study found that the treatment efficacy was significantly high in people who inject drugs, comparable to those who do not inject drugs. Factors such as stable housing and older age contributed to better adherence to therapy.

HARM REDUCTION JOURNAL (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

An update on direct antiviral agents for the treatment of hepatitis C

Carol Stanciu et al.

Summary: The development of DAA therapy has revolutionized the treatment of HCV infection, offering high efficacy, minimal side effects, and a short treatment duration. Despite the high success rate of DAA, a small percentage of patients may still fail to achieve a sustained virological response. Looking ahead, the landscape of HCV treatment is expected to evolve with more pan-genotypic treatment options becoming available to all patients in the next five years.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

Nese Demirturk et al.

Summary: The study investigated the efficacy and safety of sofosbuvir-based therapies in treating chronic hepatitis C in 525 patients, showing a high SVR rate and good tolerability without severe adverse events. Patients with HCV genotype 2 should receive more efficacious treatment.

TURKISH JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness

Nahed A. Makhlouf et al.

Summary: The study evaluated the efficacy of ledipasvir/sofosbuvir for chronic HCV in adolescents, showing significant improvement in liver stiffness at SVR12 in all groups. Treatment was well tolerated with a 100% SVR12 rate in all groups.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis

Yukihisa Yuri et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease A real-life experience

Sherief Abd-Elsalam et al.

MEDICINE (2020)

添加到收藏夹

Article Immunology

Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents

Brianna L. Norton et al.

OPEN FORUM INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?

Amr Elsayed et al.

BMJ OPEN GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Gamal Shiha et al.

GUT (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

Peter Ferenci et al.

JOURNAL OF VIRAL HEPATITIS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus /- ribavirin in real world hepatitis C patients

Nicole Loo et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV)

Vasily Isakov et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

S. Zeuzem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

Paul Y. Kwo et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Infectious Diseases

Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study

N. Tozun et al.

CLINICAL MICROBIOLOGY AND INFECTION (2015)

添加到收藏夹

Article Urology & Nephrology

A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease

Yi-Chun Chen et al.

KIDNEY INTERNATIONAL (2014)

添加到收藏夹

Article Medicine, General & Internal

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam Afdhal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Medicine, General & Internal

ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Peter Ferenci et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Public, Environmental & Occupational Health

Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis

Ross J. Harris et al.

EUROPEAN JOURNAL OF PUBLIC HEALTH (2012)

添加到收藏夹

Article Medicine, General & Internal

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Fred Poordad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Medicine, General & Internal

Telaprevir for Retreatment of HCV Infection

Stefan Zeuzem et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

F Fabrizi et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.